Table 1.
Demographic Characteristics of the Study Participants at Enrollment (Exposed Set)
| Characteristic | 30 RSV-PreF (n = 100) | 60 RSV-PreF (n = 99) | 120 RSV-PreF (n = 99) | Control (n = 102) |
|---|---|---|---|---|
| Age at vaccination, y | ||||
| Mean (SD) | 30.2 (6.7) | 29.1 (7.2) | 29.6 (7.1) | 29.9 (6.9) |
| Range | 18–45 | 18–44 | 18–44 | 20–44 |
| Geographic ancestry, No. (%) | ||||
| Asiana | 1 (1.0) | 1 (1.0) | 1 (1.0) | 1 (1.0) |
| African/African American | 1 (1.0) | 0 (0.0) | 2 (2.0) | 1 (1.0) |
| White, Caucasian/European | 96 (96.0) | 97 (98.0) | 93 (93.9) | 98 (96.1) |
| White, Arabic/North African | 0 (0.0) | 1 (1.0) | 2 (2.0) | 1 (1.0) |
| Other | 2 (2.0) | 0 (0.0) | 1 (1.0) | 1 (1.0) |
Case groups refer to groups of women who received 1 dose of the unadjuvanted RSV vaccine containing 30, 60, or 120 μg of RSV PreF. Control refers to the group of women who received 1 dose of the placebo.
Abbreviations: PreF, prefusion F protein; RSV, respiratory syncytial virus; SD, standard deviation.
aAsian refers to participants of Central/South Asian, East Asian, Japanese, or Southeast Asian heritage.